title: Statin as a Combined Therapy for Advanced-Stage Ovarian Cancer: A Propensity Score Matched Analysis.
abstract: Background. Despite the great achievements in the treatment of advanced-stage ovarian cancer, it is still a severe condition with an unfavorable 5-year survival rate. Statins have been suggested to reduce the risk of several cancers beyond their cholesterol-lowing effects. However, the prognostic significance of statins in patients with advanced-stage ovarian cancer remains controversial.Methods. A retrospective study was performed to evaluate the association between statin intake and overall survival (OS) among patients with advanced-stage ovarian cancer. Patients who underwent cytoreductive surgery followed by courses of intravenous chemotherapy were matched through a propensity score analysis.Results. A total of 60 propensity-matched patients were included. Women in statin group showed a similar OS than the nonstatin counterparts (P= 0.966), whereas residual tumor was significantly associated with better OS (P= 0.013) and was an independent factor that associated with OS (P= 0.002, hazard ratio = 5.460, and 95% confidence interval: 1.894 to 15.742) in multivariable analysis.Conclusions. Our results suggested that statin usage was not associated with improved OS in patients with advanced-stage ovarian cancer undergoing surgery and chemotherapy. Considering the retrospective nature and the relative small sample size of the study, further prospective studies and random control trials are needed.
authors.affiliation: Department of Gynecology and Obstetrics, Heilongjiang Provincial Hospital, Harbin 150036, China.
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Chen
authors.affiliation: School of Computer Science and Technology, Harbin University of Science and Technology, Harbin 150080, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Gynecology and Obstetrics, Heilongjiang Provincial Hospital, Harbin 150036, China.
authors.forename: Qiu-Hong
authors.initials: QH
authors.lastname: Xu
authors.affiliation: Department of Gynecology and Obstetrics, Heilongjiang Provincial Hospital, Harbin 150036, China.
authors.forename: Li
authors.initials: L
authors.lastname: Yan
authors.affiliation: Department of Radiology, Heilongjiang Provincial Hospital, Harbin 150036, China.
authors.forename: Xue-Feng
authors.initials: XF
authors.lastname: Gao
authors.affiliation: Department of Pathology, Heilongjiang Provincial Hospital, Harbin 150036, China.
authors.forename: Yan-Hong
authors.initials: YH
authors.lastname: Lu
authors.affiliation: Department of Gynecology and Obstetrics, Heilongjiang Provincial Hospital, Harbin 150036, China.
authors.forename: Li
authors.identifier: 0000-0001-8492-8022
authors.initials: L
authors.lastname: Wang
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D057216:Propensity Score; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors